Rozhl Chir. 2022 Spring;101(4):154-162. doi: 10.33699/PIS.2022.101.4.154-162.
The incidence of inflammatory bowel disease is increasing worldwide and, despite advances in conservative and surgical treatment, a significant proportion of patients do not achieve complete remission and have to undergo repeated surgical procedures. Stem cell therapy is a new alternative to immunomodulatory therapy.
We performed a systematic review of the literature dealing with the use of mesenchymal stem cells for the treatment of IBD. The PubMed database was searched and original studies published between 2015 and 2021 were included.
A total of 80 citations were found, of which 21 clinical studies and 47 experimental studies were included in the review.
The efficacy of MSCs in the treatment of perianal Crohns disease is at least comparable to current therapies. A positive effect of MSC administration has also been demonstrated in animal models of luminal disease or enterocutaneous fistula. The results after systemic administration in IBD patients are still ambiguous.
inflammatory bowel disease.
炎症性肠病的发病率在全球范围内呈上升趋势，尽管保守和手术治疗有所进展，但仍有相当一部分患者未达到完全缓解，需要反复进行手术。干细胞疗法是免疫调节治疗的一种新选择。
我们对涉及间充质干细胞治疗炎症性肠病的文献进行了系统回顾。检索了 PubMed 数据库，并纳入了 2015 年至 2021 年发表的原始研究。
共发现 80 篇引文，其中 21 项临床研究和 47 项实验研究被纳入综述。
MSC 在治疗肛周克罗恩病方面的疗效至少与目前的治疗方法相当。MSC 给药在腔疾病或肠皮瘘的动物模型中也显示出积极的效果。在炎症性肠病患者中全身给药后的结果仍不明确。
炎症性肠病。
